| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 10/08/2009 | WO2009123221A1 Pyrimidine derivative having cell-protecting activity and use thereof |
| 10/08/2009 | WO2009123174A1 Preparation of type a2 botulinum neurotoxin |
| 10/08/2009 | WO2009121623A2 Compounds for treating muscular dystrophy |
| 10/08/2009 | US20090253797 Creatine oral supplementation using creatine hydrochloride salt |
| 10/08/2009 | US20090253743 Compositions of tolperisone |
| 10/08/2009 | US20090253679 New imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular cdc7 |
| 10/08/2009 | US20090253623 Gh secretagogues and uses thereof |
| 10/08/2009 | CA2720343A1 Heterocyclic derivative and use thereof |
| 10/08/2009 | CA2720049A1 Pyrimidine derivative having cell protecting effect and uses thereof |
| 10/08/2009 | CA2685716A1 Compounds for treating muscular dystrophy |
| 10/07/2009 | EP1385550B1 Therapeutic medicaments for inducing tolerance |
| 10/07/2009 | EP1180036B1 Cell therapy for chronic stroke |
| 10/07/2009 | CN100546977C New compounds for the inhibition of rotamases and use thereof |
| 10/07/2009 | CN100546648C Transdermal botulinum toxin compositions |
| 10/06/2009 | US7598293 Antidiabetic agents, antilipemic agents, dietetics, anticholesterol agents, hypotensive agents, cardiovascular disorders; (S)-Ethyl 2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl) propylamino}phenyl]propionate |
| 10/06/2009 | US7598277 cancer, inflammatory, autoimmune, infectious and viral diseases , destructive bone disorders, proliferative and neurodegenerative disorders; 2-(5-fluoro-2-tolyl)-4-(4-aminocarbonylpiperazinylmethyl)-6-[a-aminocarbonyl-2,6-dichlorobenzyl]pyridine |
| 10/06/2009 | US7598272 Kinase inhibitors |
| 10/06/2009 | US7598260 CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| 10/06/2009 | US7598244 (S)-1-(3-ethoxy-1-methylpropyl)-3-[7-(3,4-methylenedioxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]urea; preventive and/or therapeutic agent for immunological rejection and/or graft versus host reaction in organ/bone marrow transplant, autoimmune disease, allergic disease and/or inflammatory disease |
| 10/06/2009 | CA2438622C Compositions containing creatine and creatinine |
| 10/01/2009 | WO2009120815A2 Therapeutic compositions and methods |
| 10/01/2009 | WO2009120304A1 Thrombin derived peptides for smooth muscle relaxation |
| 10/01/2009 | WO2009044383A8 Nucleic acid codifying for a utrophin transcription specific regulating protein, protein codified thereby and uses thereof |
| 10/01/2009 | US20090247613 Chemically synthesized nucleic acid molecule with a pyrimidine modification; cancer, ocular disease, and other proliferative disorders; neovascularization, diabetic retinopathy, restenosis and polycystic kidney disease |
| 10/01/2009 | US20090247606 RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| 10/01/2009 | US20090247456 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 10/01/2009 | US20090246147 Delivery Of Antipsychotics Through An Inhalation Route |
| 10/01/2009 | CA2722621A1 Thrombin derived peptides for smooth muscle relaxation |
| 09/30/2009 | EP2105497A1 Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom |
| 09/30/2009 | CN101543500A Dhea composition and method |
| 09/30/2009 | CN100544726C DHEA composition and method |
| 09/29/2009 | US7595316 2-(1-Cyclopentylpiperidin-4-yloxy)-5-(4-cyanophenyl)pyrimidine, for example; exhibits histamine receptor H3 antagonist or inverse agonist activity and is useful for the treatment and/or prevention of obesity, diabetes, hormonal secretion abnormality, sleep disorders |
| 09/29/2009 | CA2481263C Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system |
| 09/29/2009 | CA2348391C Chromenone and chromanone derivatives as integrin inhibitors |
| 09/29/2009 | CA2259148C Solid oral dosage forms of valsartan |
| 09/24/2009 | WO2009115321A1 Midazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators |
| 09/24/2009 | US20090239900 Quinine and quinidine salts, methods for making them, and pharmaceutical formulations comprising them |
| 09/24/2009 | US20090239877 Novel 1,2,4-triazole derivatives and process of manufacturing thereof |
| 09/24/2009 | US20090239839 Receptor antagonist |
| 09/24/2009 | CA2718558A1 Midazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as_melanocortin-4 receptor modulators |
| 09/23/2009 | EP2103614A1 Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators |
| 09/23/2009 | EP1482928B1 Mediators of hedgehog signaling pathways,compositions and uses related thereto |
| 09/23/2009 | CN101538218A Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases |
| 09/23/2009 | CN101537115A Chinese medicinal preparation for treating myasthenia gravis |
| 09/22/2009 | US7592455 potent and selective inhibitors of p38 kinase, especially p38 alpha , p38 beta and p38 beta 2; immune or inflammatory disorders; Ethyl 3-(benzylamino)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate |
| 09/22/2009 | US7592450 used to inhibit proliferative conditions, such as cancer and psoriasis, with improved bioavailability and stability |
| 09/22/2009 | US7591949 Method for the improvement of transport across adaptable semi-permeable barriers |
| 09/22/2009 | CA2426349C Over-coated chewing gum formulations including tableted center |
| 09/22/2009 | CA2398274C Adenosine receptor modulators |
| 09/22/2009 | CA2377128C Composition for the prevention of muscle fatigue and skeletal muscle adaptation to strenuous exercise |
| 09/17/2009 | WO2009114597A1 Apoaequorin-containing compositions and methods of using same |
| 09/17/2009 | WO2009079562A3 Compositions and methods for treating and preventing skeletal muscle deficiencies |
| 09/17/2009 | WO2008084368A8 Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
| 09/17/2009 | CA2717322A1 Apoaequorin-containing compositions and methods of using same |
| 09/16/2009 | EP2100893A1 Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists |
| 09/16/2009 | EP2100876A2 New compounds for the inhibition of rotamases and use thereof |
| 09/16/2009 | EP2099471A2 Uses of cerberus, coco and derivatives thereof |
| 09/16/2009 | EP1414825B9 Thienopyrimidinediones and their use in the modulation of autoimmune disease |
| 09/16/2009 | CN101530620A Triphosadenine intercalated houghite membrane and preparation method thereof |
| 09/16/2009 | CN101530479A Traditional Chinese medicine for treating diabetes mellitus complicated by muscle atrophy |
| 09/16/2009 | CN101530397A Phloroglucinol freeze-dried powder injection composition for injection |
| 09/16/2009 | CN100540058C Use of IL-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases |
| 09/15/2009 | US7589125 2-acetoxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid; methyl 2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoate; psoriasis and other immune diseases |
| 09/15/2009 | US7589091 2(R)-Benzyloxymethyl-4-[4-(4-chloro-phenyl)-piperazin-1-yl]-N-hydroxy-3(S)-(4-methoxy-phenyl)-4-oxo-butyramide; inhibiting matrix metalloproteinase; immunosuppression; neuropathic pain |
| 09/15/2009 | CA2359463C Novel polyhydroxypyrazine derivatives, preparation and pharmaceutical compositions containing same |
| 09/15/2009 | CA2342985C Hydroxamate-containing cysteine and serine protease inhibitors |
| 09/15/2009 | CA2340021C Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis |
| 09/10/2009 | US20090228998 Induction of exon skipping in eukaryotic cells |
| 09/10/2009 | US20090227558 Amino-derivatives as novel inhibitors of histone deacetylase |
| 09/10/2009 | US20090227517 Myostatin binding agents |
| 09/10/2009 | US20090226375 MICRO-RNAs THAT MODULATE SMOOTH MUSCLE PROLIFERATION AND DIFFERENTIATION AND USES THEREOF |
| 09/09/2009 | EP2098229A1 Nerve regeneration agent |
| 09/09/2009 | EP2097095A2 Myostatin inhibition for enhancing muscle and/or improving muscle function |
| 09/09/2009 | EP1509621B1 Diagnostic of alzheimer's disease by analysis of il-10 gene polymorphisms |
| 09/09/2009 | EP1002068B1 Mutations in the myostatin gene cause double-muscling in mammals |
| 09/09/2009 | CN100537571C Imidazo[1,2-a]pyrazin-8-ylamines, method of making and method of use thereof |
| 09/09/2009 | CN100537520C N-bridged selective androgen receptor modulators and methods of use thereof |
| 09/09/2009 | CN100536919C Interferon antagon and usage of Flt3L antagon |
| 09/09/2009 | CN100536915C 神经毒素植入物 Neurotoxin implant |
| 09/09/2009 | CN100536839C Urea derivatives as integrin alpha 4 antagonists |
| 09/08/2009 | US7585835 GASP1: a follistatin domain containing protein |
| 09/08/2009 | US7585507 Nucleic acid molecules and polypeptides for immune modulation |
| 09/08/2009 | CA2360360C Piperidyl benzamide compounds, composition containing same and their use thereof |
| 09/08/2009 | CA2342739C Azetidine derivatives, preparation and medicines containing them |
| 09/03/2009 | US20090221693 Novel use of organic compounds |
| 09/03/2009 | US20090221611 Fused Triazole Tachykinin Receptor Antagonists |
| 09/03/2009 | US20090221506 Gdnf derived peptides |
| 09/03/2009 | US20090220491 Binding agents which inhibit myostatin |
| 09/02/2009 | EP2095826A1 Nerve elongation promoter and elongation inhibitor |
| 09/02/2009 | EP1965669B1 Composition comprising oligosaccharides as soluble dietary fibres for use against muscle wasting |
| 09/02/2009 | EP1470137B1 Edg receptor agonists |
| 09/02/2009 | EP1458392B1 Acridones as inhibitors of impdh enzyme |
| 09/02/2009 | CN101518648A Soluble receptor BR43x2 and methods of using |
| 09/01/2009 | US7582644 Pyrimidyl sulphone amide derivatives as chemokine receptor modulators |
| 09/01/2009 | US7582619 Administering pyrimidine nucleotide precursor where respiratory chain dysfunction is caused by mutation, deletion, or rearrangement of mitochondrial DNA, cytotoxic cancer chemotherapy agents, aging |
| 09/01/2009 | US7582425 Identifying subjects who have or are at risk for developing Hereditary Spastic Paraplegia by detecting the presence or absence of one or more variations in the atlastin gene or treating HSP by administering atlastin |
| 09/01/2009 | US7582313 Methods of organ regeneration using Hox 11-expressing pluripotent cells |
| 09/01/2009 | CA2379147C Percutaneously absorbable preparations |
| 08/27/2009 | WO2009105691A2 Uses of pentamidine and related compounds |
| 08/27/2009 | WO2009104807A1 Composition for modulating stem cell growth with prostaglandins |